Thromboprophylaxis in Oesophageal Cancer Patients

• Status: Recruiting
• Trial end date: 2024-05-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of the study is to examine the efficacy and safety of prolonged thromboprophylactic treatment with Fragmin® in oesophageal cancer patients undergoing intended curative surgery.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Aarhus
• Collaborator: Aarhus University Hospital
• Treatments: Dalteparin; Heparin; Heparin, Low-Molecular-Weight; Tinzaparin

Criteria

Inclusion Criteria:

1. Cancer located in oesophagus and/or cardia.

2. Candidate for intended curative surgery.

3. Age > 18 years.

Exclusion Criteria:

1. Known inherited bleeding disorder.

2. Unable to provide informed consent.

3. Arterial or venous thromboembolic events within the last three months.

4. On-going anticoagulant treatment (Vitamin K antagonists or direct oral anticoagulants).

5. Pregnant or has given birth within the last three months.

6. Known allergy to the trial drug Dalteparin (Fragmin®).